Loading
Every dated change on the records linked to Myeloproliferative neoplasms (PV, ET, myelofibrosis), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Momelotinib improved symptom response, transfusion independence and spleen response compared with danazol; approved in September 2023.
MOMENTUM: symptom, spleen and transfusion-independence benefit versus danazol.
Cardiovascular death or major thrombosis 2.
Klampfl and Nangalia find CALR exon 9 mutations in most JAK2-negative ET/PMF.
CYTO-PV: keeping haematocrit <45% cuts cardiovascular death and major thrombosis in PV.
Spleen volume reduction of 35 percent or more at 24 weeks in 41.
Spleen volume reduction of at least 35 percent at week 48 in 28 percent of patients on ruxolitinib against 0 percent on best available therapy; European approval in 2012.
Composite of thrombosis, serious haemorrhage or vascular death more frequent with anagrelide (odds ratio 1.
Four groups report the mutation in most PV and half of ET/PMF; the first molecular marker for BCR-ABL1-negative MPN.